sarcoidosis

サルコイドーシス

　

WordNet

1. a chronic disease of unknown cause marked by the formation of nodules in the lungs and liver and lymph glands and salivary glands

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/09/15 22:03:26」(JST)

wiki en

[Wiki en表示]

Sarcoidosis
Chest X-ray showing the typical nodularity of sarcoidosis in the base of the lungs.
Classification and external resources
Specialty	Rheumatology
ICD-10	D86
ICD-9-CM	135
OMIM	181000
DiseasesDB	11797
MedlinePlus	000076
eMedicine	med/2063
Patient UK	Sarcoidosis
MeSH	D012507

Sarcoidosis, also called sarcoid, is a disease involving abnormal collections of inflammatory cells (granulomas) that can form as nodules in multiple organs. The granulomas are most often located in the lungs or its associated lymph nodes, but any organ can be affected. Sarcoidosis seems to be caused by an immune reaction to an infection or some other trigger (called an antigen) that continues even after the initial infection or other antigen is cleared from the body. In most cases it clears up by itself without any medical intervention, but some cases go on to affect the person long-term or become life-threatening and require medical intervention, most often with medications. 1 alpha, 25(OH)2 Vitamin D3 is the main cause for high blood calcium in sarcoidosis and is overproduced by sarcoid granulomata. Gamma-interferon produced by activated lymphocytes and macrophages plays a major role in the synthesis of 1 alpha, 25(OH)2 Vitamin D3.

Treatment is usually designed to help relieve the symptoms and thus does not directly alter the course of the disease. This treatment usually consists of anti-inflammatory drugs like ibuprofen or aspirin. In cases where the condition develops to the point that it has a progressive and/or life-threatening course, the treatment is most often steroid treatment with prednisone or prednisolone. Alternatively, drugs that are most commonly used to treat cancer and suppress the immune system, such as methotrexate, azathioprine and leflunomide, may be used. The average mortality rate is less than 5% in untreated cases.

In the United States it most commonly affects people of Northern European (especially Scandinavian or Icelandic) or African/African American ancestry between the ages of 20 and 29, although any race or age group can be affected. Japan has a lower rate of sarcoidosis than the United States, although in these people the disease is usually more aggressive in its course with the heart often affected. Japanese individuals also have a different peak age for sarcoidosis, 25–40 years of age. It occurs about twice as often in women, where it usually takes a more aggressive course. In developing countries, it often goes misdiagnosed as tuberculosis (TB) as its symptoms often resemble those of TB.

Sarcoidosis was first described in 1877 by an English doctor named Dr. Jonathan Hutchinson as a skin disease causing red, raised lesions on the arms, face, and hands.

Signs and symptoms

Signs and symptoms of sarcoidosis.

Systemic sarcoidosis

Sarcoidosis is a systemic inflammatory disease that can affect any organ, although it can be asymptomatic and is discovered by accident in about 5% of cases. Common symptoms, which tend to be vague, include fatigue (unrelieved by sleep; occurs in 66% of cases), lack of energy, weight loss, joint aches and pains (which occur in about 70% of cases), arthritis (14–38% of persons), dry eyes, swelling of the knees, blurry vision, shortness of breath, a dry, hacking cough, or skin lesions. Less commonly, people may cough up blood. The cutaneous symptoms vary, and range from rashes and noduli (small bumps) to erythema nodosum, granuloma annulare, or lupus pernio. Sarcoidosis and cancer may mimic one another, making the distinction difficult.

The combination of erythema nodosum, bilateral hilar lymphadenopathy, and joint pain is called Löfgren syndrome which has a relatively good prognosis. This form of the disease occurs significantly more commonly in Scandinavian patients, than in those of non-Scandinavian origin.

Respiratory tract

Localization to the lungs is by far the most common manifestation of sarcoidosis. At least 90% of affected persons experience lung involvement. Overall, about 50% develop permanent pulmonary abnormalities, and 5 to 15% have progressive fibrosis of the lung parenchyma. Sarcoidosis of the lung is primarily an interstitial lung disease in which the inflammatory process involves the alveoli, small bronchi and small blood vessels. In acute and subacute cases, physical examination usually reveals dry rales. At least 5% of persons will suffer pulmonary arterial hypertension. Less commonly, the upper respiratory tract (including the larynx, pharynx, and sinuses) may be affected, which occurs in between 5 and 10% of cases.

Sarcoidosis of the lungs can be divided into four stages. Stage 0 — No intrathoracic involvement. Stage I — Bilateral hilar adenopathy. Stage II — Pulmonary parenchyma involved. Stage III — Pulmonary infiltrates with fibrosis. Stage 4 is end-stage lung disease with pulmonary fibrosis and honeycombing.

Skin

Main article: Cutaneous manifestations of sarcoidosis

Sarcoidosis involves the skin in between 9 and 37% of persons and is more common in African Americans than in their white counterparts. The skin is the second most commonly affected organ, after the lungs. The most common lesions are erythema nodosum, plaques, maculopapular eruptions, subcutaneous nodules, and lupus pernio. Treatment is not required, since the lesions usually resolve spontaneously in two to four weeks. Although it may be disfiguring, cutaneous sarcoidosis rarely causes major problems. Sarcoidosis of the scalp presents with diffuse or patchy hair loss.

Heart

The frequency of cardiac involvement varies and is significantly influenced by race; in Japan over 25% of persons with sarcoidosis experience symptomatic cardiac involvement, whereas in the US and Europe only about 5% of cases present with cardiac involvement. Autopsy studies in the US have revealed a frequency of cardiac involvement of about 20–30%, whereas autopsy studies in Japan have shown a frequency of 60%. The presentation of cardiac sarcoidosis can range from asymptomatic conduction abnormalities to fatal ventricular arrhythmia. Conduction abnormalities are the most common cardiac manifestations of sarcoidosis among persons and can include complete heart block. Second to conduction abnormalities, in frequency, are ventricular arrhythmias and occurs in about 23% of persons with cardiac involvement. Sudden cardiac death, either due to ventricular arrhythmias or complete heart block is a rare complication of cardiac sarcoidosis. Cardiac sarcoidosis can cause fibrosis, granuloma formation or the accumulation of fluid in the interstitium of the heart or a combination of the former two.

Eye

Eye involvement occurs in about 10–90% of cases. Manifestations in the eye include uveitis, uveoparotitis, and retinal inflammation, which may result in loss of visual acuity or blindness. The most common ophthalmologic manifestation of sarcoidosis is uveitis. The combination of anterior uveitis, parotitis, VII cranial nerve paralysis and fever is called uveoparotid fever or Heerfordt syndrome (D86.8). Development of scleral nodule associated with sarcoidosis have been observed.

Nervous system

Main article: Neurosarcoidosis

Any of the components of the nervous system can be involved. Sarcoidosis affecting the nervous system is known as neurosarcoidosis. Cranial nerves are most commonly affected, accounting for about 5–30% of neurosarcoidosis cases, and peripheral facial nerve palsy, often bilateral, is the most common neurological manifestation of sarcoidosis. It occurs suddenly and is usually transient. The central nervous system involvement is present in 10–25% of sarcoidosis cases. Other common manifestations of neurosarcoid include optic nerve dysfunction, papilledema, palate dysfunction, neuroendocrine changes, hearing abnormalities, hypothalamic and pituitary abnormalities, chronic meningitis, and peripheral neuropathy. Myelopathy, that is spinal cord involvement, occurs in about 16–43% of neurosarcoidosis cases and is often associated with the poorest prognosis of the neurosarcoidosis subtypes. Whereas facial nerve palsies and acute meningitis due to sarcoidosis tends to have the most favourable prognosis. Another common finding in sarcoidosis with neurological involvement is autonomic or sensory small fiber neuropathy. Neuroendocrine sarcoidosis accounts for about 5–10% of neurosarcoidosis cases and can lead to diabetes insipidus, changes in menstrual cycle and hypothalamic dysfunction. The latter can lead to changes in body temperature, mood and prolactin (see the endocrine and exocrine section for details).

Endocrine and exocrine

Prolactin is frequently increased in sarcoidosis, between 3% and 32% of cases have hyperprolactinemia this frequently leads to amenorrhea, galactorrhea, or nonpuerperal mastitis in women. It also frequently causes an increase in 1,25-dihydroxy vitamin D, the active metabolite of vitamin D, which is usually hydrolysed within the kidney, but in sarcoidosis patients hydroxylation of vitamin D can occur outside the kidneys, namely inside the immune cells found in the granulomas the condition produces. 1 alpha, 25(OH)2D3 is the main cause for hypercalcemia in sarcoidosis and overproduced by sarcoid granulomata. Gamma-interferon produced by activated lymphocytes and macrophages plays a major role in the synthesis of 1 alpha, 25(OH)2D3. Hypercalciuria (excessive secretion of calcium in one's urine) and hypercalcemia (an excessively high amount of calcium in the blood) are seen in <10% of individuals and likely results from the increased 1,25-dihydroxy vitamin D production. Thyroid dysfunction is seen in 4.2–4.6% of cases.

Parotid enlargement occurs in about 5–10% of persons. Bilateral involvement is the rule. The gland is usually not tender, but firm and smooth. Dry mouth can occur; other exocrine glands are affected only rarely. The eyes, their glands, or the parotid glands are affected in 20%-50% of cases.

Gastrointestinal and genitourinary

Symptomatic GI involvement occurs in less than 1% of persons (note that this is if one excludes the liver), and most commonly the stomach is affected, although the small or large intestine may also be affected in a small portion of cases. Studies at autopsy have revealed GI involvement in less than 10% of people. These cases would likely mimic Crohn's disease, which is a more commonly intestine-affecting granulomatous disease. About 1–3% of people have evidence of pancreatic involvement at autopsy. Symptomatic kidney involvement occurs in just 0.7% of cases, although evidence of kidney involvement at autopsy has been reported in up to 22% of people and occurs exclusively in cases of chronic disease. Symptomatic kidney involvement is usually nephrocalcinosis, although granulomatous interstitial nephritis that presents with reduced creatinine clearance and little proteinuria is a close second. Less commonly, the epididymis, testicles, prostate, ovaries, fallopian tubes, uterus, or the vulva may be affected, the latter may cause vulva itchiness. Testicular involvement has been reported in about 5% of people at autopsy. In males, sarcoidosis may lead to infertility.

Around 70% of people have granulomas in their livers, although only in about 20–30% of cases liver function test anomalies reflecting this fact are seen. About 5–15% of persons exhibit hepatomegaly, that is an enlarged liver. Only 5–30% of cases of liver involvement are symptomatic. Usually, these changes reflect a cholestatic pattern and include raised levels of alkaline phosphatase (which is the most common liver function test anomaly seen in persons with sarcoidosis), while bilirubin and aminotransferases are only mildly elevated. Jaundice is rare.

Hematologic and immunologic

Abnormal clinical blood tests are frequent, accounting for over 50% of cases, but is not diagnostic. Lymphopenia is the most common hematologic anomaly in sarcoidosis. Anemia occurs in about 20% of people with sarcoidosis. Leukopenia is less common and occurs in even fewer persons but is rarely severe. Thrombocytopenia and hemolytic anemia are fairly rare. In the absence of splenomegaly, leukopenia may reflect bone marrow involvement, but the most common mechanism is a redistribution of blood T cells to sites of disease. Other nonspecific findings include monocytosis, occurring in the majority of sarcoidosis cases, increased hepatic enzymes or alkaline phosphatase. People with sarcoidosis often have immunologic anomalies like allergies to test antigens such as Candida or purified protein derivative (PPD). Polyclonal hypergammaglobulinemia is also a fairly common immunologic anomaly seen in sarcoidosis.

Lymphadenopathy (swollen glands) is common in sarcoidosis and occurs in 15% of cases. Intrathoracic nodes are enlarged in 75 to 90% of all people; usually this involves the hilar nodes, but the paratracheal nodes are commonly involved. Peripheral lymphadenopathy is very common, particularly involving the cervical (the most common head and neck manifestation of the disease), axillary, epitrochlear, and inguinal nodes. Approximately 75% of cases show microscopic involvement of the spleen, although only in about 5–10% of cases does splenomegaly appear.

Bone, joints, and muscles

Bone involvement in sarcoidosis has been reported in 1–13% of cases. About 5–15% of cases affect the bones, joints, or muscles.

Causes

The exact cause of sarcoidosis is not known. The current working hypothesis is, in genetically susceptible individuals, sarcoidosis is caused through alteration to the immune response after exposure to an environmental, occupational, or infectious agent. Some cases may be caused by treatment with TNF inhibitors like etanercept.

Genetics

The heritability of sarcoidosis varies according to race, about 20% of African Americans with sarcoidosis have a family member with the condition, whereas the same figure for whites is about 5%. Investigations of genetic susceptibility yielded many candidate genes, but only few were confirmed by further investigations and no reliable genetic markers are known. Currently, the most interesting candidate gene is BTNL2; several HLA-DR risk alleles are also being investigated. In persistent sarcoidosis, the HLA haplotype HLA-B7-DR15 are either cooperating in disease or another gene between these two loci is associated. In nonpersistent disease, there is a strong genetic association with HLA DR3-DQ2. Cardiac sarcoid has been connected to TNFA variants.

Infectious agents

Several infectious agents appear to be significantly associated with sarcoidosis, but none of the known associations is specific enough to suggest a direct causative role. The major implicated infectious agents include: mycobacteria, fungi, borrelia, and rickettsia. A recent meta-analysis investigating the role of mycobacteria in sarcoidosis found it was present in 26.4% of cases, but the meta-analysis also detected a possible publication bias, so the results need further confirmation. Mycobacterium tuberculosis catalase-peroxidase has been identified as a possible antigen catalyst of sarcoidosis. The disease has also been reported by transmission via organ transplants.

Autoimmune

Association of autoimmune disorders has been frequently observed. The exact mechanism of this relation is not known, but some evidence supports the hypothesis that this is a consequence of Th1 lymphokine prevalence. Tests of delayed cutaneous hypersensitivity have been used to measure progression.

Pathophysiology

Granulomatous inflammation is characterized primarily by accumulation of monocytes, macrophages, and activated T-lymphocytes, with increased production of key inflammatory mediators, TNF, IFN-γ, IL-2, IL-8, IL-10, IL-12, IL-18, IL-23 and TGF-β, indicative of a Th1-mediated immune response. Sarcoidosis has paradoxical effects on inflammatory processes; it is characterized by increased macrophage and CD4 helper T-cell activation, resulting in accelerated inflammation, but immune response to antigen challenges such as tuberculin is suppressed. This paradoxic state of simultaneous hyper- and hypoactivity is suggestive of a state of anergy. The anergy may also be responsible for the increased risk of infections and cancer.

The regulatory T-lymphocytes in the periphery of sarcoid granulomas appear to suppress IL-2 secretion, which is hypothesized to cause the state of anergy by preventing antigen-specific memory responses. Schaumann bodies seen in sarcoidosis are calcium and protein inclusions inside of Langhans giant cells as part of a granuloma.

While TNF is widely believed to play an important role in the formation of granulomas (which is further supported by the finding that in animal models of mycobacterial granuloma formation inhibition of either TNF or IFN-γ production inhibits granuloma formation), sarcoidosis can and does still develop in persons being treated with TNF antagonists like etanercept. B cells also likely play a role in the pathophysiology of sarcoidosis. Serum levels of soluble HLA class I antigens and ACE are higher in persons with sarcoidosis. Likewise the ratio of CD4/CD8 T cells in bronchoalveolar lavage is usually higher in persons with pulmonary sarcoidosis (usually >3.5), although it can be normal or even abnormally low in some cases. Serum ACE levels have been found to usually correlate with total granuloma load.

Cases of sarcoidosis have also been reported as part of the immune reconstitution syndrome of HIV, that is, when people receive treatment for HIV their immune system rebounds and the result is that it starts to attack the antigens of opportunistic infections caught prior to said rebound and the resulting immune response starts to damage healthy tissue.

• Sarcoidosis in a lymph node

• Asteroid body in sarcoidosis

• Micrograph showing pulmonary sarcoidosis with granulomas with asteroid bodies, H&E stain

Diagnosis

Diagnosis of sarcoidosis is a matter of exclusion, as there is no specific test for the condition. To exclude sarcoidosis in a case presenting with pulmonary symptoms might involve chest X-ray, CT scan of chest, PET scan, CT-guided biopsy, mediastinoscopy, open lung biopsy, bronchoscopy with biopsy, endobronchial ultrasound, and endoscopic ultrasound with FNA of mediastinal lymph nodes (EBUS FNA). Tissue from biopsy of lymph nodes is subjected to both flow cytometry to rule out cancer and special stains (acid fast bacilli stain and Gömöri methenamine silver stain) to rule out microorganisms and fungi.

Serum markers of sarcoidosis, include: serum amyloid A, soluble interleukin 2 receptor, lysozyme, angiotensin converting enzyme, and the glycoprotein KL-6. Angiotensin-converting enzyme blood levels are used in the monitoring of sarcoidosis. A bronchoalveolar lavage can show an elevated (of at least 3.5) CD4/CD8 T cell ratio, which is indicative (but not proof) of pulmonary sarcoidosis. In at least one study the induced sputum ratio of CD4/CD8 and level of TNF was correlated to those in the lavage fluid.

Differential diagnosis includes metastatic disease, lymphoma, septic emboli, rheumatoid nodules, granulomatosis with polyangiitis, varicella infection, tuberculosis, and atypical infections, such as Mycobacterium avium complex, cytomegalovirus, and cryptococcus. Sarcoidosis is confused most commonly with neoplastic diseases, such as lymphoma, or with disorders characterized also by a mononuclear cell granulomatous inflammatory process, such as the mycobacterial and fungal disorders.

CT scan of the chest showing lymphadenopathy (arrows) in the mediastinum due to sarcoidosis

Chest X-ray changes are divided into four stages:

• Stage 1: bihilar lymphadenopathy
• Stage 2: bihilar lymphadenopathy and reticulonodular infiltrates
• Stage 3: bilateral pulmonary infiltrates
• Stage 4: fibrocystic sarcoidosis typically with upward hilar retraction, cystic and bullous changes

Although people with stage 1 X-rays tend to have the acute or subacute, reversible form of the disease, those with stages 2 and 3 often have the chronic, progressive disease; these patterns do not represent consecutive "stages" of sarcoidosis. Thus, except for epidemiologic purposes, this X-ray categorization is mostly of historic interest.

In sarcoidosis presenting in the Caucasian population, hilar adenopathy and erythema nodosum are the most common initial symptoms. In this population, a biopsy of the gastrocnemius muscle is a useful tool in correctly diagnosing the person. The presence of a noncaseating epithelioid granuloma in a gastrocnemius specimen is definitive evidence of sarcoidosis, as other tuberculoid and fungal diseases extremely rarely present histologically in this muscle.

Classification

Sarcoidosis may be divided into the following types:

• Annular sarcoidosis
• Erythrodermic sarcoidosis
• Ichthyosiform sarcoidosis
• Hypopigmented sarcoidosis
• Löfgren syndrome
• Lupus pernio
• Morpheaform sarcoidosis
• Mucosal sarcoidosis
• Neurosarcoidosis
• Papular sarcoid
• Scar sarcoid
• Subcutaneous sarcoidosis
• Systemic sarcoidosis
• Ulcerative sarcoidosis

Treatment

Most persons (>75%) only require symptomatic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or aspirin. For persons presenting with lung symptoms, unless the respiratory impairment is devastating, active pulmonary sarcoidosis is observed usually without therapy for two to three months; if the inflammation does not subside spontaneously, therapy is instituted. Corticosteroids, most commonly prednisone or prednisolone, have been the standard treatment for many years. In some people, this treatment can slow or reverse the course of the disease, but other people do not respond to steroid therapy. The use of corticosteroids in mild disease is controversial because in many cases the disease remits spontaneously. Despite their widespread use, the evidence supporting corticosteroid use is weak at best.

Severe symptoms are generally treated with corticosteroids although steroid-sparing agents such as azathioprine, methotrexate, mycophenolic acid, and leflunomide are often used as alternatives. Of these, methotrexate is most widely used and studied. Methotrexate is considered a first-line treatment in neurosarcoidosis, often in conjunction with corticosteroids. Long-term treatment with methotrexate is associated with liver damage in about 10% of people and hence may be a significant concern in people with liver involvement and requires regular liver function test monitoring. Methotrexate can also lead to pulmonary toxicity (lung damage), although this is fairly uncommon and more commonly it can confound the leukopenia caused by sarcoidosis. Due to these safety concerns it is often recommended that methotrexate is combined with folic acid in order to prevent toxicity. Azathioprine treatment can also lead to liver damage. Leflunomide is being used as a replacement for methotrexate, possibly due to its purportedly lower rate of pulmonary toxicity. Mycophenolic acid has been used successfully in uveal sarcoidosis, neurosarcoidosis (especially CNS sarcoidosis; minimally effective in sarcoidosis myopathy), and pulmonary sarcoidosis.

As the granulomas are caused by collections of immune system cells, particularly T cells, there has been some success using immunosuppressants (like cyclophosphamide, cladribine, chlorambucil, and cyclosporine), immunomodulatory (pentoxifylline and thalidomide), and anti-tumor necrosis factor treatment (such as infliximab, etanercept, golimumab, and adalimumab).

In a clinical trial cyclosporine added to prednisone treatment failed to demonstrate any significant benefit over prednisone alone in people with pulmonary sarcoidosis, although there was evidence of increased toxicity from the addition of cyclosporine to the steroid treatment including: infections, malignancies (cancers), hypertension, and kidney dysfunction. Likewise chlorambucil and cyclophosphamide are seldom used in the treatment of sarcoidosis due to their high degree of toxicity, especially their potential for causing malignancies. Infliximab has been used successfully to treat pulmonary sarcoidosis in clinical trials in a number of persons. Etanercept, on the other hand, has failed to demonstrate any significant efficacy in people with uveal sarcoidosis in a couple of clinical trials. Likewise golimumab has failed to show any benefit in persons with pulmonary sarcoidosis. One clinical trial of adalimumab found treatment response in about half of subjects, which is similar to that seen with infliximab, but as adalimumab has better tolerability profile it may be preferred over infliximab.

Ursodeoxycholic acid has been used successfully as a treatment for cases with liver involvement. Thalidomide has also been tried successfully as a treatment for treatment-resistant lupus pernio in a clinical trial, which may stem from its anti-TNF activity, although it failed to exhibit any efficacy in a pulmonary sarcoidosis clinical trial. Cutaneous disease may be successfully managed with antimalarials (such as chloroquine and hydroxychloroquine) and the tetracycline antibiotic, minocycline. Antimalarials have also demonstrated efficacy in treating sarcoidosis-induced hypercalcemia and neurosarcoidosis. Long-term use of antimalarials is limited, however, by their potential to cause irreversible blindness and hence the need for regular ophthalmologic screening. This toxicity is usually less of a problem with hydroxychloroquine than with chloroquine, although hydroxychloroquine can disturb the glucose homeostasis.

Recently selective phosphodiesterase 4 (PDE4) inhibitors like apremilast (a thalidomide derivative), roflumilast, and the less subtype-selective PDE4 inhibitor, pentoxifylline, have been tried as a treatment for sarcoidosis, with successful results being obtained with apremilast in cutaneous sarcoidosis in a small open-label study. Pentoxifylline has been used successfully to treat acute disease although its use is greatly limited by its gastrointestinal toxicity (mostly nausea, vomiting, and diarrhea). Case reports have supported the efficacy of rituximab, an anti-CD20 monoclonal antibody and a clinical trial investigating atorvastatin as a treatment for sarcoidosis is under-way. ACE inhibitors have been reported to cause remission in cutaneous sarcoidosis and improvement in pulmonary sarcoidosis, including improvement in pulmonary function, remodeling of lung parenchyma and prevention of pulmonary fibrosis in separate case series'. Nicotine patches have been found to possess anti-inflammatory effects in sarcoidosis patients, although whether they had disease-modifying effects requires further investigation. Antimycobacterial treatment (drugs that kill off mycobacteria, the causative agents behind tuberculosis and leprosy) has also proven itself effective in treating chronic cutaneous (that is, it affects the skin) sarcoidosis in one clinical trial. Quercetin has also been tried as a treatment for pulmonary sarcoidosis with some early success in one small trial.

Because of its uncommon nature, the treatment of male reproductive tract sarcoidosis is controversial. Since the differential diagnosis includes testicular cancer, some recommend orchiectomy, even if evidence of sarcoidosis in other organs is present. In the newer approach, testicular, epididymal biopsy and resection of the largest lesion has been proposed.

Prognosis

Gross pathology image showing sarcoidosis with honeycombing: Prominent honeycombing is present in the lower lobes accompanied by fibrosis and some honeycombing in the upper lungs. Honeycombing consists of cystically dilated airways separated by scar tissue resembling the honeycomb of bees. It is a nonspecific end stage of many types of interstitial lung disease.

The disease can remit spontaneously or become chronic, with exacerbations and remissions. In some persons, it can progress to pulmonary fibrosis and death. About half of cases resolve without treatment or can be cured within 12–36 months, and most within five years. Some cases, however, may persist several decades. Two-thirds of people with the condition achieve a remission within 10 years of the diagnosis. When the heart is involved, the prognosis is generally less favourable, although, corticosteroids appear effective in improving AV conduction. The prognosis tends to be less favourable in African Americans, compared to white Americans. Persons with sarcoidosis appear to be at significantly increased risk for cancer, in particular lung cancer, lymphomas, and cancer in other organs known to be affected in sarcoidosis. In sarcoidosis-lymphoma syndrome, sarcoidosis is followed by the development of a lymphoproliferative disorder such as non-Hodgkin lymphoma. This may be attributed to the underlying immunological abnormalities that occur during the sarcoidosis disease process. Sarcoidosis can also follow cancer or occur concurrently with cancer. There have been reports of hairy cell leukemia, acute myeloid leukemia, and acute myeloblastic leukemia associated with sarcoidosis.

Epidemiology

Sarcoidosis most commonly affects young adults of both sexes, although studies have reported more cases in females. Incidence is highest for individuals younger than 40 and peaks in the age-group from 20 to 29 years; a second peak is observed for women over 50.

Sarcoidosis occurs throughout the world in all races with an average incidence of 16.5 per 100,000 in men and 19 per 100,000 in women. The disease is most common in Northern European countries and the highest annual incidence of 60 per 100,000 is found in Sweden and Iceland. In the United Kingdom the prevalence is 16 in 100,000. In the United States, sarcoidosis is more common in people of African descent than Caucasians, with annual incidence reported as 35.5 and 10.9 per 100,000, respectively. Sarcoidosis is less commonly reported in South America, Spain, India, Canada, and the Philippines. There may be a higher susceptibility to sarcoidosis in those with celiac disease. An association between the two disorders has been suggested.

There also has been a seasonal clustering observed in sarcoidosis-affected individuals. In Greece about 70% of diagnoses occur between March and May every year, in Spain about 50% of diagnoses occur between April and June, and in Japan it is mostly diagnosed during June and July.

The differing incidence across the world may be at least partially attributable to the lack of screening programs in certain regions of the world, and the overshadowing presence of other granulomatous diseases, such as tuberculosis, that may interfere with the diagnosis of sarcoidosis where they are prevalent. There may also be differences in the severity of the disease between people of different ethnicities. Several studies suggest the presentation in people of African origin may be more severe and disseminated than for Caucasians, who are more likely to have asymptomatic disease. Manifestation appears to be slightly different according to race and sex. Erythema nodosum is far more common in men than in women and in Caucasians than in other races. In Japanese persons, ophthalmologic and cardiac involvement are more common than in other races.

It is more common in certain occupations, namely firefighters, educators, military personnel, persons who work in industries where pesticides are used, law enforcement, and healthcare personnel. In the year after the September 11 attacks, the rate of sarcoidosis incidence went up four-fold (to 86 cases per 100,000).

History

It was first described in 1877 by Dr. Jonathan Hutchinson, a dermatologist as a condition causing red, raised rashes on the face, arms, and hands. In 1888 the term Lupus pernio was coined by Dr. Ernest Besnier, another dermatologist. Later in 1892 lupus pernio's histology was defined. In 1902 bone involvement was first described by a group of three doctors. Between 1909 and 1910 uveitis in sarcoidosis was first described, and later in 1915 it was emphasised, by Dr. Schaumann, that it was a systemic condition. This same year lung involvement was also described. In 1937 uveoparotid fever was first described and likewise in 1941 Löfgren syndrome was first described. In 1958 the first international conference on sarcoidosis was called in London, likewise the first USA sarcoidosis conference occurred in Washington, DC in the year 1961. It has also been called Besnier-Boeck disease or Besnier-Boeck-Schaumann disease.

Society and culture

The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) is an organisation of physicians involved in the diagnosis and treatment of sarcoidosis and related conditions. WASOG publishes the journal Sarcoidosis, Vasculitis, and Diffuse Lung Diseases. Additionally, the Foundation for Sarcoidosis Research (FSR) is devoted to supporting research into sarcoidosis and its possible treatments.

There have been concerns that World Trade Center rescue workers are at a heightened risk for sarcoidosis.

In 2014, in a letter to the British medical journal The Lancet, it was suggested that the French Revolution leader Maximilien Robespierre suffered from sarcoidosis, and suggested that the condition caused him a notable impairment during his time as the head of the Reign of Terror.

Etymology

The word "sarcoidosis" comes from Greek [σάρκο-] sarcο- meaning "flesh", the suffix -(e)ido (from the Greek εἶδος -eidos [usually omitting the initial e in English as the diphthong epsilon-iota in Classic Greek stands for a long "i" = English ee]) meaning "type", " resembles" or "like", and -sis, a common suffix in Greek meaning "condition". Thus the whole word means "a condition that resembles crude flesh". The first cases of sarcoïdosis, which were recognised as a new pathological entity, in scandinavia, at the end of the 19th century exhibited skin nodules resembling cutaneous sarcomas, hence the name initially given.

Pregnancy

Sarcoidosis generally does not prevent successful pregnancy and delivery; the increase in estrogen levels during pregnancy may even have a slightly beneficial immunomodulatory effect. In most cases, the course of the disease is unaffected by pregnancy, with improvement in a few cases and worsening of symptoms in very few cases, although it is worth noting that a number of the immunosuppressants (such as methotrexate, cyclophosphamide, and azathioprine) used in corticosteroid-refractory sarcoidosis are known teratogens.

References

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. サルコイドーシスの肺外の症状 extrapulmonary manifestations of sarcoidosis
• 2. 肺サルコイドーシスの臨床症状および診断 clinical manifestations and diagnosis of pulmonary sarcoidosis
• 3. 心サルコイドーシス cardiac sarcoidosis
• 4. サルコイドーシスの皮膚症状 cutaneous manifestations of sarcoidosis
• 5. ステロイドによる肺サルコイドーシスの治療 treatment of pulmonary sarcoidosis with glucocorticoids

English Journal

• Medullary neurosarcoidosis presenting with intractable hiccoughs.

• John S, Parambil J, Culver D, Tavee J.SourceDepartment of Neurology, Cleveland Clinic, 9500 Euclid Avenue S10-C, Cleveland, OH 44195, USA.
• Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.J Clin Neurosci.2012 Aug;19(8):1193-5. Epub 2012 May 19.
• Hiccoughs (singultus) are a complex physiological process characterized by sudden brief involuntary contractions of the diaphragm. They most commonly occur from peripheral mechanisms that result in diaphragmatic irritation, but also occur from brain stem lesions such as that seen in Wallenberg's syn
• PMID 22613488

• Severe calcification of the aorta (porcelain aorta) associated with sarcoidosis in a pediatric heart transplant recipient.

• Das BB, Shoemaker L, Kim E, Mascio CE, Austin EH.SourceDivision of Pediatric Cardiology, Department of Pediatrics Division of Pediatric Nephrology Division of Cardiovascular and Thoracic Surgery, University of Louisville School of Medicine, Louisville, KY, USA.
• Pediatric transplantation.Pediatr Transplant.2012 Aug;16(5):E162-6. doi: 10.1111/j.1399-3046.2011.01557.x. Epub 2011 Aug 23.
• Das BB, Shoemaker L, Kim E, Mascio CE, Austin EH. Severe calcification of the aorta (porcelain aorta) associated with sarcoidosis in a pediatric heart transplant recipient. Abstract:  We report a unique case of severe calcification of the aorta, bilateral coronary ostial stenoses and calcification
• PMID 21883745

Japanese Journal

• Positron Emission Tomography-Computed Tomography for Imaging of Inflammatory Cardiovascular Diseases : Sarcoidosis, Large-Vessel Arteritis, and Atherosclerosis

• Miyagawa Masao,Yokoyama Rami,Nishiyama Yoshiko [他]
• Circulation journal : official journal of the Japanese Circulation Society 78(6), 1302-1310, 2014-06
• NAID 40020065603

• 症例 サルコイドーシスに選択的IgM欠損症を合併した1例

• 豊田 学,三野 健,黒瀬 嘉幸 [他]
• 内科 113(4), 779-782, 2014-04
• NAID 40020028670

• 病理学的側面からみた心サルコイドーシス

• 宇都 健太,小田 秀明,西川 俊郎,UTO Kenta,ODA Hideaki,NISHIKAWA Toshio
• 東京女子医科大学雑誌 84(臨時増刊2(西川俊郎教授退任記念特別)), E244-E249, 2014-03-31
• NAID 120005430891

Related Links

• Sarcoidosisとは - goo Wikipedia (ウィキペディア)

Sarcoidosis involves the skin in between 9 and 37% of persons and is more common in African Americans than in their white counterparts. [2] The skin is the second most commonly affected organ, after the lungs. [21] The most ...

• What Is Sarcoidosis? - NHLBI, NIH

Sarcoidosis (sar-koy-DO-sis) is a disease of unknown cause that leads to inflammation. This disease affects your body’s organs. Normally, your immune system defends your body against foreign or harmful substances.

Related Pictures

---

★リンクテーブル★

リンク元	「サルコイドーシス」「高カルシウム血症」「急性尿細管間質性腎炎」「infiltrative disorder」「類肉腫症」
拡張検索	「cardiac sarcoidosis」「pulmonary sarcoidosis」

「サルコイドーシス」

　　[★]

英

sarcoidosis

同

サルコイド症、ベック病 Boeck disease、ベック類肉腫 Boeck sarcoid Boeck's sarcoid、ベニエー・ベック・シャウマン病 morbus Besnier-Boeck-Schaumann、血管類狼瘡 angio-lupoide

関

難病

概念

• 特定疾患治療研究事業の対象となっている難病である。
• 原因不明の全身性疾患

病因

• P. acnes?が抗原としてTh細胞に提示されるため？
• HLA-DRB1*1101 are assosiated with an increased risk for developing sarcoidosis (HIM.2136)

疫学

• 若年と中年に好発。
• 北に多く南に少ない。黒人に多い。HLAやサイトカイン遺伝子が関与か？

病型

• ヘールフォルト症候群 Heefordt症候群：ぶどう膜炎・耳下腺腫脹・顔面神経麻痺が主徴。微熱を伴って発症。
• ロフグレン症候群 Lofgren症候群：結節性紅斑、BHL、関節痛の三徴候を伴う。急性で白人女性に多い。

病理

• 非乾酪性類上皮細胞肉芽腫
• サルコイド肉芽腫
• 類上皮細胞
• 巨細胞：ラングハンス型巨細胞、異物型巨細胞

• asteroid bodyやSchaumann bodyを含むことがある　→　サルコイドーシスに特異的ではない(結核、らい病、foreign-body reaction, necrobiotic xanthogranuloma)

• 皮膚

• 真皮および皮下組織に、結合組織に被包された類上皮細胞の特徴的な島嶼状結節性の肉芽腫がある。
• 皮膚では複数の類上皮細胞肉芽腫が主に真皮の上中層に生じる。ときに真皮深層、皮下組織、筋層に生じうる。

症候

無症状での検診発見例が大多数。微熱などの症状を出して来院することはまれ。

• 肺病変　：両側肺門リンパ節腫脹(bilateral hilar lymphadenopathy, BHL)：胸部X線所見の割には無症状。
• 眼病変　：両眼性霧視(ぶどう膜炎、硝子体炎)
• 心病変　：心サルコイドーシス。心ブロック、不整脈、Adams-Stokes症候群
• 皮膚病変：2型ある。結節型、びまん浸潤型が多く、古い瘢痕(肘、膝)にサルコイド肉芽腫ができることがある。この肉芽腫を病理診断に使うと浸襲が少ない。

• 肉芽腫病変(皮膚サルコイド)
• 炎症の反応性病変(結節性紅斑)

• 内分泌異常：高ACE活性、高カルシウム血症
• その他・・無痛性表在リンパ節腫大や心病変(まれだが本症の急死の原因)脳神経(致死的)

病変部位の頻度

• 肺（縦隔・肺門リンパ節，肺）95％以上
• 眼（ぶどう膜，網膜，硝子体）30-40％
• 皮膚5-10％

表在リンパ節腫脹のみられることがあり，時に心臓病変がみられる。

YN I-112

• 初発症状：眼(眼前霧視)50%、呼吸器症状15%、皮膚症状5-10%、両側耳下腺腫脹、リンパ節腫脹

検査

• 血算

• リンパ球：減少 (T細胞の減少によるらしい)

• 血液生化学

• カルシウム：上昇(日本人には稀)
• ビタミンD3：上昇(日本人には稀)
• 副甲状腺ホルモン関連蛋白(PTHrP)：上昇(日本人には稀)
• ガンマグロブリン：上昇
• アンジオテンシン転換酵素：上昇
• 血清リゾチーム活性：上昇　　　←　単球の崩壊
• 可溶性インターロイキン2レセプター(sIL-2R)：上昇することがある

• 血清免疫学的検査：

• ツベルクリン反応：70%の症例で陰性化 or 減弱

• 生検：病理的に非乾酪性類上皮細胞肉芽腫を証明する。経気管支的肺生検や前斜角筋生検が行われる。
• 画像検査

• 胸部単純X線写真：両側肺門部リンパ節腫脹(BHL)、びまん性陰影、結節影、空洞病変、網状影、浸潤影、小粒状影

• 分類(I～III型)：(I型)BHL、(II型)BHL+肺野病変、(III型)肺野病変。I型が最多。

• 胸部CT：縦隔リンパ腺腫脹、血管・気管支周囲の肥厚・不整像、胸膜不整像
• ガリウムシンチグラム(67Ga)：病変部に集積。
• テクネシウムシンチグラム(99mTc)：病変部に欠損像
• タリウムシンチグラム(201Tl)：灌流欠損像
• PET：高集積

• 気管支鏡検査：気管分岐部周囲や両主気管支に毛細血管の増生・拡張や腫大したリンパ節による圧排像を認めうる。気管支内にサルコイド結節(肉芽腫)を認めうる。
• 気管支肺胞洗浄

• 細胞数増加
• リンパ球増加
• CD4/CD8比：高値 (喫煙者でも上昇しうる)　　→　　液性免疫優位。血清γグロブリン上昇はこのためか？

• 皮膚生検、皮下結節生検、表在リンパ節生検、前斜角筋リンパ節生検、肝生検、縦隔・肺門部リンパ節生検：非乾酪性類上皮細胞肉芽腫の証明

診断

• 胸部X線像
• 臨床症状
• 組織生検像

診断基準

参考1

• 基準

組織診断群(確実)　　：1-(2)のいずれかの臨床・検査所見があり，1－(3)が陽性。

臨床診断群(ほぼ確実)：1-(2)①，②のいずれかの臨床所見があり，1－(2)③の(a)（ツベリクリン反応）又は(c)（血清ACE）を含む3 項目以上陽性。

• 除外規定

• 1. 原因既知あるいは別の病態の疾患、例えば悪性リンパ腫、結核、肺癌(癌性リンパ管症)、ベリリウム肺、塵肺、過敏性肺炎など。
• 2. 異物、癌等によるサルコイド局所反応。

• 1 主要事項

• (1) 臨床症状：呼吸器症状（咳・息切れ），眼症状（霧視），皮膚症状（丘疹）など。
• (2) 臨床所見・検査所見

• ① 胸郭内病変

• (a) 胸部X 線・CT 所見（両側肺門リンパ節腫脹，びまん性陰影，血管・胸膜の変化など）
• (b) 肺機能所見（％VC・DLco・PaO2 の低下）
• (c) 気管支鏡所見（粘膜下血管のnetwork formation，結節など）
• (d) 気管支肺胞洗浄液所見※1（総細胞数・リンパ球の増加，CD4／8 上昇）
• (e) 胸腔鏡所見（結節，肥厚，胸水など）

• ② 胸郭外病変

• (a) 眼病変（前部ぶどう膜炎，隅角結節，網膜血管周囲炎など）　→　眼サルコイドーシス
• (b) 皮膚病変（結節，局面，びまん性浸潤，皮下結節，瘢痕浸潤）
• (c) 表在リンパ節病変（無痛性腫脹）
• (d) 心病変（伝導障害，期外収縮，心筋障害など）　→　心サルコイドーシス
• (e) 唾液腺病変（耳下腺腫脹，角結膜乾燥，涙腺病変など）
• (f) 神経系病変（脳神経，中枢神経障害など）
• (g) 肝病変（黄疸，肝機能上昇，結節など）
• (h) 骨病変（手足短骨の骨梁脱落など）
• (i) 脾病変（腫脹など）
• (j) 筋病変（腫瘤，筋力低下，萎縮など）
• (k) 腎病変（持続性蛋白尿，高カルシウム血症，結石など）
• (l) 胃病変（胃壁肥厚，ポリープなど）

• ③ 検査所見

• (a) ツベルクリン反応陰性
• (b) γグロブリン上昇
• (c) 血清ACE 上昇
• (d) 血清リゾチーム上昇
• (e) 67Ga 集積像陽性（リンパ節，肺など）
• (f) 気管支肺胞洗浄液の総細胞数・リンパ球増加，CD4／8 上昇

• (3) 病理組織学的所見

• 類上皮細胞からなる乾酪性壊死を伴わない肉芽腫病変生検部位（リンパ節，経気管支肺生検，気管支壁，皮膚，肝，筋肉，心筋，結膜など）。クベイム反応も参考になる

治療

• stage0やⅠ(BHL)では経過観察
• stageⅡ(BHL＋肺陰影)、Ⅲ(肺陰影のみ)、Ⅳ(肺繊維化)では

• 1ステロイド(8割)　2免疫抑制剤メソトレキセート・アザチオプリン(難治性2割に)

予後

• 70%は2年以内に自然寛解。5-10%は難治性に進行。
• 死因の60%は心サルコイドーシスであり、心病変(刺激伝導障害)をきたす。

参考

• 1. サルコイドーシス - 難病情報センター

http://www.nanbyou.or.jp/entry/266

• 2. 認定基準 - 難病情報センター

http://www.nanbyou.or.jp/upload_files/043_s.pdf

• 3. 日本サルコイドーシス学会

http://www.jssog.com/www/top/shindan/shindankijyun.html

「高カルシウム血症」

　　[★]

英

hypercalcemia

同

高Ca血症

関

カルシウム、低カルシウム血症

研修医当直御法度 症例帳 p.32

• 組織へのカルシウム蓄積を引き起こしうる (BPT.27)

病因

• 1. 原発性副甲状腺機能亢進症(甲状腺腺腫などによるPTHの分泌亢進)
• 2. 腫瘍に随伴

• 2-1. 肺の扁平上皮癌、成人性Ｔ細胞白血病→PTH関連蛋白(PTHrP)の分泌
• 2-2. 腫瘍の骨転移により、破骨細胞が骨破壊。

• 3. サルコイドーシス、肉芽細胞→異所性1,25(OH)2D3が発生する。

• 肉芽の構成成分であるマクロファージがビタミンD3を産生？

• 4. サイアザイド系利尿薬や骨粗しょう症の薬として1,25(OH)2D3製剤。

• 4-1. サイアザイド系利尿薬

• チアジド系利尿薬の慢性使用により体液量が減少し、近位尿細管での再吸収が亢進するため (GOO.755)　？？
• チアジド系利尿薬自体のDCTでの作用による；NCCTを阻害すると細胞内のNa濃度低下、これにより側底膜でのNa+-Ca2+交換系が亢進することでCa2+の再吸収↑ (GOO.755) 　→　ループ利尿薬と違ってチアジド系利尿薬ははCaを排泄しない！！ see.利尿薬

• 5. 家族性低Ca尿性高Ca血症
• 6. その他(リチウム？？？？ (ICU.558))

ECGP.223

• 7. ビタミンA, ビタミンDの中毒
• 8. 腎不全
• 9. 副腎不全

USMLEより

• Caused by calcium ingestion (milk-alkali syndrome), hyperparathyroid, hyperthyroid, iatrogenic (thiazides), multiple myeloma, Paget's disease, Addison's disease, Neoplasms, Zollinger-Ellison syndrome, Excess vitamin D, Excess vitamin A, sarcoidosis.

• Calcium ingestion
• Hyperparathyroid/Hyperthyroid
• Iatrogenic
• Multiplemyeloma
• Paget's disease
• Addison's disease
• Neoplasms
• Zollinger-Ellison syndrome: ZES単独ではなく、MEN Iによるparathyroid tumorに続発した病態
• Excessive vitamin D
• Excessive vitamin A
• Sarcoidosis

定義

• 血清カルシウムが正常上限を超える場合。

• 疑い：常に≧10.3 mg/dl
• 確実：≧10.5 mg/dl

↑

基準値

• 血清総Ca 8.6-10.1 mg/dl(臨床検査法提要第32版)
• 血清Caイオン 1.15-1.30 mmmol/l(臨床検査法提要第32版), 4.6-5.1 mg/dl

症候

軽度(11-11.5 mg/dL)：通常は無症状。(HIM.285)

重度(>12-13 mg/dL)：傾眠、昏迷、昏睡、消化器症状が出現。(HIM.285)

• 精神・神経症状：錯乱、昏迷、昏睡。イライラ感、うつ傾向(QB.D-339)
• 消化器：食欲不振、悪心・嘔吐、便秘。膵炎、消化性潰瘍。腹部膨満(腸管運動抑制による(QB.D-339))

• 消化性潰瘍：高カルシウム血症は胃酸分泌を促進する
• 急性膵炎：高カルシウム血症は膵液の分泌を亢進する。(YN.B-78)　←　過剰に出ちゃうと炎症が起こってしまうらしい

• 泌尿器：多尿、腎結石(血清Ca 12mg/dLでできやすくなるらしい)　←　多尿は浸透圧利尿による(ICU.558)

• 急性腎不全

• 腎不全は一般的に低カルシウム血症となるが、高カルシウム血症に起因する腎不全は例外。

→高カルシウム血症性腎症 hypercalcemic nephropathy

• 腎の石灰化→髄質に蓄積→尿細管圧迫→尿濃縮力障害　←　続発性尿崩症の原因？？？

• 高カルシウム血症は腎の濃縮力を低下させる(HIM.286)　←　腎集合管におけるADHの作用を阻害(QB.D-339)

• 心血管：血管収縮による高血圧(出典不明！！)。徐脈、房室ブロック、QT短縮(HIM.284)。　←　YN.D-147には血圧上昇、ICU.558には低血圧とある。
• 筋　：筋力低下、筋痛
• 全身：易疲労感

• 異所性石灰化 red eye　強膜にカルシウムが沈着
• 多尿による脱水、高血圧、徐脈

心電図

EAB.114 SP.94,524

• QT短縮、ST短縮　←　活動電位持続時間が短縮したことを示す。QRS幅については延長する場合もある(EAB.114)

• ↑細胞外カルシウム濃度→↑内向きカルシウム電流(↑流入速度)→さらに脱分極するように思えるが↑外向きカリウム電流により打ち消される→正味、カルシウムの移動が無くなるまでの時間が早まる→↓活動電位持続時間

• PR間隔延長？？

高カルシウム血症→QT短縮：　←高カリウム血症

低カルシウム血症→QT延長：　←低カリウム血症　低マグネシウム血症

治療

• 症状が出たときか、症状無く血清Ca 14mg/dL以上の場合(ICU.558)

生理食塩水

• 1. 細胞外液の補充
• 2. ナトリウム利尿によるカルシウム排泄の促進

高カルシウム血症の鑑別

		尿中のCa排泄	PTH	PTHrP	1,25(OH)2D3
原発性甲状腺機能亢進症	↑	↑	↓	→　or　↑
腫瘍のPTH関連蛋白分泌	↑	↓	↑	↓
	 腫瘍の骨破壊	↑	↓	↓	↓
	 肉芽腫症		↓	↓	↓	→　or　↑

参考

• http://akimichi.homeunix.net/~emile/aki/html/medical/endocrine/node52.html

国試

• 102G052

「急性尿細管間質性腎炎」

　　[★]

英

acute tubulointerstitial nephritis

同

急性間質性腎炎 acute interstitial nephritis, AIN

関

尿細管間質性腎炎

原因

• 薬剤性

• antibiotics (lactams, sulfonamides, quinolones, vancomycin, erythromycin, minocycline, rifampin, ethambutol, acyclovir)
• NSAIDs,COX-2阻害薬
• 利尿薬(thiazides, furosemide, triamterene)
• 抗てんかん薬(フェニトイン、フェノバルビタール、カルバマゼピン、バルプロ酸)
• その他(カプトプリル、H2受容体阻害薬、プロトンポンプ阻害薬、mesalazine、indinavir、アロプリノール)

• 感染症

• 細菌(Streptococcus、Staphylococcus、Legionella、Salmonella、Brucella、Yersinia、Corynebacterium diphtheriae)
• ウイルス(Epstein-Barr virus、cytomegalovirus、Hantavirus、polyomavirus、HIV)
• その他(レプトスピラ、リケッチア、マイコプラズマ)

• 特発性

• tubulointerstitial nephritis-uveitis syndrome
• anti-tubule basement membrane disease
• sarcoidosis

「infiltrative disorder」

　　[★]

• a condition caused by the diffusion or accumulation in cells or tissues of substances not normally found in those cells or tissues, as in granulomatous diseases.

• ex.

• amyloidosis, sarcoidosis

「類肉腫症」

　　[★]

英

sarcoidosis

関

サルコイドーシス、多臓器肉芽腫性疾患

「cardiac sarcoidosis」

　　[★] 心サルコイドーシス、心臓サルコイドーシス

「pulmonary sarcoidosis」

　　[★] 肺サルコイドーシス